ESTRO 2022 | Stereotactic body radiotherapy and concomitant systemic therapy for oligoprogressive breast cancer

Luca Nicosia, MD, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, explains a study on patients with oligoprogressive breast cancer treated with stereotactic body radiotherapy (SBRT) and concomitant systemic therapy. The study explored the effectiveness of SBRT in delaying the time to next systemic treatment (NEST) in patients treated with SBRT during the first or second treatment cycle. It was found that SBRT delayed NEST by a median time of 8 months. Multivariate analysis found that the number of treated oligometastases was a significant factor in determining NEST. Importantly, patients with more than one oligometastatic legion had a significantly shorter NEST so patients with only one metastasis are likely to benefit the most from SBRT. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.